Abstract:
The present invention provides a compound of formula I wherein X", R1, and R2 are as defined herein, and compositions thereof. The compounds include and are based on an impurity of methylnaltrexone, a peripheral opioid antagonist.
Abstract:
Provided are peptide fragments which may be used in a method of producing a synthetic peptide, or a conjugate comprised of the synthetic peptide operatively linked to fatty acid, wherein the method comprises chemically coupling 2 or more peptide fragments together in a process of assembly to produce the synthetic peptide or conjugate.
Abstract:
Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
Abstract:
Provided is a method for site-specific chemical modification of an HIV gp41 -derived peptide, wherein during synthesis one or more amine groups of the HIV gp41 -derived peptide are chosen to blocked by a chemical protecting agent, and one or more amine groups are selected to be unprotected, and remain free to be reacted with an amine reactive functionality. The resultant HIV gp41-derived peptide may be used to produce a substantially homogeneous conjugate comprised of HIV gp41-derived peptide and polymer by covalently coupling the polymer to the one or more free (unprotected) amine groups of the HIV gp41-derived peptide.
Abstract:
Provided is a conjugate comprised of HIV gp41 -derived peptide operatively linked to fatty acid, and pharmaceutical compositions and medicaments containing the conjugate. Also provided are methods for producing a conjugate according to the present invention which include, but are not limited to, covalently coupling a linker to the HIV gp41 -derived peptide, wherein the linker is covalently coupled to fatty acid.
Abstract:
Provided are peptide fragments which may be used in a method of producing a synthetic peptide, or a conjugate comprised of the synthetic peptide operatively linked to fatty acid, wherein the method comprises chemically coupling 2 or more peptide fragments together in a process of assembly to produce the synthetic peptide or conjugate.
Abstract:
The present invention provides a compound of formula I: wherein X - , R 1 , and R 2 are as defined herein, and compositions thereof. The compounds are peripheral opioid receptors.
Abstract:
Provided is a conjugate comprised of HIV gp41 -derived peptide operatively linked to fatty acid, and pharmaceutical compositions and medicaments containing the conjugate. Also provided are methods for producing a conjugate according to the present invention which include, but are not limited to, covalently coupling a linker to the HIV gp41 -derived peptide, wherein the linker is covalently coupled to fatty acid.
Abstract:
Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
Abstract:
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9. SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.